15 September 2022 | Other

Pfizer begins final phase of mRNA-based flu vaccine trials

Pfizer Inc. has begun conducting the final phase of a flu vaccine trial in the United States. The final phase of the trial will involve 25,000 patients. This is one of the first such trials for an mRNA-based flu vaccine.

Pfizer Inc reported that first participants have already received the vaccine shot. Its manufacture is based on the same technology as the common COVID-19 vaccine. The technology was developed jointly with the German organization BioNTech SE.

Between 12,000 and 52,000 people die of influenza in the U.S. each year. But vaccines use strains that require annual replacement before flu season - circulating viruses are constantly evolving.

With the advent of mRNA technology, the ability to change strains in vaccines more quickly has been achieved. Pfizer expects this to provide more accurate strain matching in the future.

Company MarketCheese
Period: 25.07.2025 Expectation: 440 pips
AUDCAD gains on technical bounce and improved sentiment in commodity markets
Today at 10:05 AM 28
Period: 25.07.2025 Expectation: 1700 pips
GBPUSD struggles to regain momentum as uptrend breaks
Today at 09:14 AM 26
Period: 25.07.2025 Expectation: 222 pips
Buying natural gas with target at 3.780 amid record heatwaves in US and Asia
Yesterday at 10:49 AM 62
Period: 25.07.2025 Expectation: 15000 pips
ETHUSD rally accelerates as US moves forward with crypto legislation
Yesterday at 10:13 AM 65
Period: 23.07.2025 Expectation: 600 pips
USDCAD gains strength amid dollar rally and falling oil prices
16 July 2025 86
Period: 25.07.2025 Expectation: 1000 pips
Nvidia's return to China pushes shares toward 180 level
16 July 2025 78
Go to forecasts